ENTERO Vu 24% — E-Z-EM Canada Inc drug label update
E-Z-EM Canada Inc updated the drug label for ENTERO Vu 24%, a radiographic contrast agent. The update clarifies that the product is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal tract in adult patients.
This update affects E-Z-EM Canada Inc, regulatory affairs professionals managing contrast media portfolios, and clinical staff involved in adult gastrointestinal radiographic imaging.
The source indicates a specific focus on adult populations for small bowel visualization. This formal labeling update suggests that clinical utilization must remain within these defined parameters to ensure regulatory compliance. While the change appears routine, such updates necessitates an audit of promotional materials and clinical use guidelines to prevent off-label communication.
Regulatory and compliance teams should verify that all current product labeling, marketing materials, and internal clinical protocols align with the specific indication for adult small bowel radiographic examinations. Quality systems should ensure the most recent label version is integrated into the supply chain documentation.
ENTERO Vu 24% (E-Z-EM Canada Inc). 1 INDICATIONS AND USAGE ENTERO VU 24% is indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (GI) tract in adult patients. ENTERO VU 24% is a radiographic contrast agent indicated for use in small bowel radiographic examinations to visualize the gastrointestinal (GI) tract in adult patients ( 1 )
Open in openFDA / FDA.gov